Immunic Inc (Nasdaq: IMUX), a New York-based biotechnology company, announced on Tuesday that it has named Jason Tardio as its new chief operating officer and president, effective 12 July 2024.

In the new role, Tardio is to head internal efforts to prepare for the potential launch of vidofludimus calcium (IMU-838), the company's orally available nuclear receptor related 1 (Nurr1) activator. He will also work closely with Patrick Walsh, chief business officer.

Tardio has worked as chief operating officer of Ovid Therapeutics Inc after joining the company as chief commercial officer. He has worked as vice president, head of the Multiple Sclerosis Franchise at Novartis AG and for nine years in positions of increasing responsibility at Biogen Inc., where he most recently served as general manager, managing director for Biogen's Latin America South affiliate. He has over two decades of experience in the biopharmaceutical industry starting at Wyeth Pharmaceuticals Inc. and Sepracor, Inc., with various roles in sales, sales training and marketing.